Columbia’s Jai Radhakrishnan, MD, MS, explains how FSGS differs by phenotype and why new IgA nephropathy drugs reach so few patients.
Jai Radhakrishnan, MD, MS
Advertisement
Articles by Jai Radhakrishnan, MD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
4
Insurance Barriers Tied to Missed Long-Acting PrEP Starts
5